News
-
-
-
PRESS RELEASE
NioCorp Announces Pricing of $50.0 Million Registered Direct Offering of Common Shares
NioCorp Developments Ltd. announces a registered direct offering of common shares in the United States, expected to raise approximately $50.0 million for corporate purposes and Elk Creek Project advancement -
-
-
-
PRESS RELEASE
Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress
Protagonist Therapeutics announces superior skin clearance data for icotrokinra compared to deucravacitinib and sustained clearance in ICONIC-LEAD study. Preclinical data on PN-881 presented at EADV Congress 2025 -
-
-